207 related articles for article (PubMed ID: 26031284)
1. [Treatment strategies for ANCA-associated vasculitides].
Hellmich B
Z Rheumatol; 2015 Jun; 74(5):388-97. PubMed ID: 26031284
[TBL] [Abstract][Full Text] [Related]
2. [De-escalation of therapy in ANCA-associated vasculitides].
Schinke S; Riemekasten G; Lamprecht P
Z Rheumatol; 2017 Feb; 76(1):15-20. PubMed ID: 27933390
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
4. [ANCA-associated vasculitis].
Holle JU
Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
6. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
7. Maintenance treatment of ANCA-associated vasculitides.
Guillevin L
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):199-201. PubMed ID: 28406765
[TBL] [Abstract][Full Text] [Related]
8. Seven clinical conundrums in the treatment of ANCA-associated vasculitis.
Alba MA; Flores-Suárez LF
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S74-83. PubMed ID: 23663685
[TBL] [Abstract][Full Text] [Related]
9. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
[TBL] [Abstract][Full Text] [Related]
10. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
11. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S; Sugiyama T; Umibe T; Kaneko Y; Amano K; Kurasawa K; Nakagomi D; Hiraguri M; Hanaoka H; Sato Y; Ikeda K; Nakajima H;
BMJ Open; 2017 Dec; 7(12):e018748. PubMed ID: 29247107
[TBL] [Abstract][Full Text] [Related]
12. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.
Miloslavsky EM; Niles JL; Wallace ZS; Cortazar FB; Fernandes A; Laliberte K; Stone JH
Semin Arthritis Rheum; 2018 Oct; 48(2):288-292. PubMed ID: 29530330
[TBL] [Abstract][Full Text] [Related]
13. The evolving treatment of ANCA-associated vasculitides.
Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
[TBL] [Abstract][Full Text] [Related]
14. 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Harigai M; Nagasaka K; Amano K; Bando M; Dobashi H; Kawakami T; Kishibe K; Murakawa Y; Usui J; Wada T; Tanaka E; Nango E; Nakayama T; Tsutsumino M; Yamagata K; Homma S; Arimua Y
Mod Rheumatol; 2019 Jan; 29(1):20-30. PubMed ID: 30001655
[TBL] [Abstract][Full Text] [Related]
15. Management of ANCA associated vasculitis.
Wallace ZS; Miloslavsky EM
BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?
Alba MA; Flores-Suárez LF
Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570
[TBL] [Abstract][Full Text] [Related]
19. [Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].
Dábague Guzmán J; Pedroza Granados J; Zúñiga Varga J
Reumatol Clin; 2011 Dec; 7 Suppl 3():S37-40. PubMed ID: 22119277
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]